Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: The CODAM study

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1900-1909

  Wlazlo, Nick ^a,b,c   Van Greevenbroek, Marleen M J ^b,c   Ferreira, Isabel ^b,c   Feskens, Edith J M ^d   Van Der Kallen, Carla J H ^b,c   Schalkwijk, Casper G ^b,c   Bravenboer, Bert ^a   Stehouwer, Coen D A ^b,c  

^a CATHARINA HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; FATTY ACID; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADIPOCYTE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; AGED; BLOOD; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHYSIOLOGY;

ADIPOCYTES; AGED; BLOOD GLUCOSE; COHORT STUDIES; COMPLEMENT C3; DIABETES MELLITUS, TYPE 2; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84903529331     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2804     Document Type: Article

References (62)

1. Onat A, Hergenç G, Can G, Kaya Z, Yüksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism 2010;59:628-634
2. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012;55:881-884
3. Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, Solá-Izquierdo E, Morillas-Ariño C, Martínez-Triguero ML. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond) 2007;31:927-932
4. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012;61:1787-1796
5. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C′3: evidence for the liver as the primary site of synthesis. Science 1969;163:286-288
6. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-12741
7. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066
8. Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013;122:3473-3481
9. Triantafilou K, Hughes TR, Triantafilou M, Morgan BP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci 2013;126:2903-2913
10. Laudisi F, Spreafico R, Evrard M, et al. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. J Immunol 2013;191:1006-1010
11. Takabayashi T, Vannier E, Clark BD, et al. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 1996;156:3455-3460
12. Fischer WH, Jagels MA, Hugli TE. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 1999;162:453-459
13. Shu CJ, Benoist C, Mathis D. The immune system's involvement in obesity-driven type 2 diabetes. Semin Immunol 2012;24:436-442
14. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012;8:709-716
15. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830
16. Chen J, Wildman RP, Hamm LL, et al.; Third National Health and Nutrition Examination Survey. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2960-2965
17. van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetesmellitus: causes and consequences. Neth J Med 2013;71:174-187
18. Krogh-Madsen R, Plomgaard P, Møller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 2006;291:E108-E114
19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
20. Bertoni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010;33:804-810
21. Muscari A, Antonelli S, Bianchi G, et al.; Pianoro Study Group. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 2007;30:2362-2368
22. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000;23:779-785
23. van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Cabezas MC. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007;190:167-173
24. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005;54:570-575
25. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin: the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study. Diabetes Care 2013;36:309-315
26. Martin RF. General deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clin Chem 2000;46:100-104
27. van Bussel BC, Ferreira I, van de Waarenburg MP, et al. Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and an electrochemiluminescense-based multiarray platform. PLoS ONE 2013;8:e58576
28. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. Eur J Clin Invest 2013;43:679-688
29. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495
30. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007;30:89-94
31. Vangipurapu J, Stančáková A, Kuulasmaa T, et al.; EGIR-RISC Study Group. A novel surrogate index for hepatic insulin resistance. Diabetologia 2011;54:540-543
32. Vangipurapu J, Stancáková A, Pihlajamäki J, et al. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. Diabetologia 2011;54:563-571
33. Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, Defronzo RA. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the antilipolytic effect of insulin. Acta Diabetol 2008;45:147-150
34. van Bussel BC, Henry RM, Schalkwijk CG, et al. Fish consumption in healthy adults is associated with decreased circulating biomarkers of endothelial dysfunction and inflammation during a 6-year follow-up. J Nutr 2011;141:1719-1725
35. Du H, van der A DL, van Bakel MM, et al. Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008;87:655-661
36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
37. Twisk JW. Different statistical models to analyze epidemiological observational longitudinal data: an example from the Amsterdam Growth and Health Study. Int J Sports Med 1997;18(Suppl. 3):S216-S224
38. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Cambridge, Cambridge University Press, 2003
39. Li SH, Huang HL, Chen YH. Ovarian steroid-regulated synthesis and secretion of complement C3 and factor B in mouse endometrium during the natural estrous cycle and pregnancy period. Biol Reprod 2002;66:322-332
40. Yilmazer M, Fenkci V, Fenkci S, Aktepe O, Sonmezer M, Kurtay G. Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women. Hum Reprod 2003;18:1531-1535
41. Wärnberg J, Nova E, Moreno LA, et al.; AVENA Study Group. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr 2006;84:505-512
42. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 1997;108:507-515
43. Hernández-Mijares A, Bañuls C, Bellod L, et al. Effect of weight loss on C3 and C4 components of complement in obese patients. Eur J Clin Invest 2012;42:503-509
44. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20:488-495
45. Engström G, Hedblad B, Janzon L, Lindgärde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia 2005;48:2525-2531
46. Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995;13:277-305
47. Kalant D, Maslowska M, Scantlebury T, Wang H, Cianflone K. Control of lipogenesis in adipose tissue and the role of acylation stimulating protein. Can J Diab 2003;27:154-171
48. Mamane Y, Chung Chan C, Lavallee G, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009;58:2006-2017
49. Schlaf G, Schieferdecker HL, Rothermel E, Jungermann K, Gotze O. Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin- induced Ca2+ release. Lab Invest 1999;79:1287-1297
50. Lim J, Iyer A, Suen JY, et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J 2013;27:822-831
51. Phieler J, Chung KJ, Chatzigeorgiou A, et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol 2013;191:4367-4374
52. Saleh J, Summers LK, Cianflone K, Fielding BA, Sniderman AD, Frayn KN. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998;39:884-891
53. Germinario R, Sniderman AD, Manuel S, Lefebvre SP, Baldo A, Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 1993;42:574-580
54. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003;1609:127-143
55. Halkes CJ, van Dijk H, de Jaegere PP, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-1530
56. Wen Y, Wang H, MacLaren R, Wu J, Lu H, Cianflone K. Palmitate and oleate induction of acylation stimulating protein resistance in 3T3-L1 adipocytes and preadipocytes. J Cell Biochem 2008;104:391-401
57. MacLaren R, Kalant D, Cianflone K. The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. Biochem Cell Biol 2007;85:11-21
58. Cui W, Paglialunga S, Kalant D, et al. Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am J Physiol Endocrinol Metab 2007;293:E1482-E1491
59. Paglialunga S, Schrauwen P, Roy C, et al. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol 2007;194:293-304
60. Weuve J, Tchetgen Tchetgen EJ, Glymour MM, et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology 2012;23:119-128
61. Wang P, Keijer J, Bunschoten A, Bouwman F, Renes J, Mariman E. Insulin modulates the secretion of proteins from mature 3T3-L1 adipocytes: a role for transcriptional regulation of processing. Diabetologia 2006;49:2453-2462
62. Koistinen HA, Vidal H, Karonen SL, et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001;21:1034-1039